Background and objectives In the Hemodialysis (HEMO) Study, observed small decreases in achieved equilibrated Kt/V urea were noncausally associated with markedly increased mortality. Here we examine the association of mortality with modeled volume (V m ), the denominator of equilibrated Kt/V urea .
Introduction
In the Hemodialysis (HEMO) Study, patients assigned to receive an equilibrated Kt/V (eKt/V) of either 1.05 or 1.45 three times weekly showed no significant differences in survival, hospitalization, nutritional status, or health-related quality of life (1, 2) . These results contrast markedly with observational studies that have consistently shown associations between higher dialysis dose and survival (3) (4) (5) . In a previous analysis of HEMO Study data, we found strong associations between the achieved dose and survival within each of the two randomized dose groups (6) . The magnitude of the association greatly exceeded the 95% confidence limits of the dose-survival relationship indicated by the intention-to-treat analysis. Within each of the two randomized dose groups, patients achieving a higher dialysis dose apparently shared clinical characteristics that were favorably associated with survival independent of dose itself. We referred to this bias as dose-targeting bias. Such a bias might be related to the numerator of dose (Kt) influenced directly by the dialysis prescription or to the denominator, the modeled urea volume, V m . This study explores the association between mortality and modeled urea volume (V m ) as another potential source of confounding of the dose-mortality association.
Patients and Methods

Study Design
The HEMO Study was a multicenter randomized clinical trial designed to compare survival, hospitalization, nutritional status, and health-related quality of life in subjects randomized to different levels of dialysis dose (i.e., eKt/V urea 1.05 or 1.45) and membrane flux (1) . A total of 1846 subjects from 72 dialysis units affiliated with 15 dialysis centers in the United States were randomized between 1995 and 2001. The dose intervention was administered with centrally generated dialysis prescriptions containing combinations of blood flow, dialysate flow, and treatment time that resulted in an expected eKt/V of 1.05 or 1.45 (single-pool Kt/V levels of approximately 1.3 and 1.7). Prescribed eKt/V urea was computed based on the subject's running mean V m over the prior four kinetic modeling (KM) sessions in the standard dose group and six KM sessions in the high dose group. Prescriptions were updated after changes in the running mean V m of Ն5% in the standard dose group and after increases of Ն5% or decreases of Ն7.5% in the high dose group. Urea KM in the HEMO trial (7-10) is described in more detail in the Appendix.
Measurements
Baseline evaluation included five case mix factors: age, gender, race (black versus nonblack), diabetes, and years of dialysis before the trial. Anthropometric total body water volume (V ant ) was estimated using the Watson formula (11). Comorbidity was summarized using the Karnofsky index (12) , the overall score from the Index of Coexisting Disease (ICED) (13, 14) , and eight subindices from the ICED evaluating specific domains. Vascular access type (fistula versus graft versus catheter), occurrence of access revisions during the previous month, number of hypotensive episodes, pre-and postdialysis weight, pre-, intra-, and postdialysis systolic and diastolic BP, interruptions, and other deviations from the dialysis prescription were extracted from the dialysis facility's flow sheets. Hospitalizations were identified by chart review and patient interview and cross-checked with Medicare records (15) .
Data Analysis
We stratified all survival analyses by clinical center and censored follow-up time at transplantation or 4 months after transfer to nonparticipating dialysis facilities. We restricted analyses of V m to modeled sessions with Ͻ15 minutes of interruption time and no obvious blood urea nitrogen (BUN) measurement errors (7, 10) .
Correlates of V m , V ant , and V m /V ant
We used mixed effects models (17, 18) to relate modeled and anthropometric volume measured monthly to individual clinical factors after controlling for the randomized dose and flux groups and five case mix factors: age, gender, race, diabetes, and vintage (years on dialysis). Vascular access type was also included as a covariate in analyses relating volume measurements to BP. Clinical factors considered and the technical details of the mixed models are described in the Appendix.
We applied a 1-month lag to the 4-month moving averages to avoid coupling with the volume-related measurements. We examined three different models for V m and V ant to distinguish among relations involving changes in V ant and relations involving changes in V m as distinct from V ant . The first two models related V m and V ant as outcome variables to the predictor variables listed above while controlling for baseline V ant . The third model related the follow-up V m /V ant ratio to the predictor variables while controlling for follow-up V ant .
Association of V m with Mortality
We used Cox regression with time-dependent covariates (18) to relate mortality at each time point to the latest 4-month running mean values of V m , V ant , or V m /V ant while controlling for the five baseline case mix variables, randomized treatment, and either baseline or follow-up V ant (see above). Our primary assessments of the association of V m with mortality were based on analyses that both factored V m for V ant and incorporated V ant as a covariate. The ratio of V m /V ant has a weaker correlation with V ant than does V m ; hence, this model provides greater robustness for assessing relations between V m and mortality than analyses relating mortality to V m while controlling for V ant . These analyses were performed in all 1846 randomized subjects.
Association of Change in V m with Mortality
We also used Cox regression with time-dependent covariates to relate mortality to the change in the 4-month moving average of V m over the preceding 6 months while controlling for the five baseline case mix variables, randomized treatment, and the 6-month lagged running mean V ant . We used a two-slope linear spline to estimate the mortality hazard ratios (HRs) separately for increases and decreases in V m . The analyses of change in V m were restricted to 1704 subjects with at least one KM session after 6 months of follow-up. The basic Cox regression for change in V m was extended by adding interaction terms to evaluate effect modification by (1) gender, (2) lower or higher V ant (V ant Յ 35 L versus V ant Ͼ 35 L), (3) diabetes, (4) subjects randomized to the standard or high dose groups, and (5) subjects with and without occurrence of a vascular access issue during the preceding 10 months (including the 6 months over which the change in V m was evaluated plus the prior 4 months). We defined a vascular access issue as one or more of the following: (1) access procedure, (2) access hospitalization, (3) change of access type, and (4) use of venous catheter. An extension of this analysis evaluated the relation between change in V m and mortality separately for subjects with and without occurrence of either an access issue or a reported shortfall in treatment time. A similar model with interaction terms was used to evaluate the HR for the 6-month change in the 4-month average V m separately for subjects with contemporaneous increases (Ն2 kg) in postdialysis weight, stable weight (absolute value of weight change Ͻ2 kg), or weight decreases (Ն2 kg), where weights were averaged over 4-month windows and changes evaluated over 6 months, similarly to V m .
Role of V m in Accounting for Dose Targeting Bias
To align each measure of V m and eKt/V urea , we used a Cox regression with time-dependent covariates to relate mortality to quintiles of prescribed eKt/V urea within each dose group while controlling for the running mean V m that was used for the current prescription, along with case mix, baseline V ant , and the randomized dose and flux groups. For details, please see the Appendix.
Results
Patient Characteristics
Baseline characteristics of the HEMO subjects have been previously described (2) . Treatment characteristics and volume-related parameters at 4 months are shown in Table  1 . After controlling for follow-up V ant , the follow-up V m /V ant ratio was associated with race (4.2 Ϯ 0.6% higher for blacks) and diabetes (2.7 Ϯ 0.5% higher for subjects with diabetes).
Follow-up factors. Table 2 shows the associations of V m and V ant with selected follow-up factors after controlling for case mix and dose and flux randomized groups. Compared with subjects with fistulas, graft use was associated with a lower V m (Ϫ1650 ml) but a higher V ant (ϩ460 ml), whereas use of catheters was associated with a higher V m (ϩ2550 ml) but lower V ant (Ϫ570 ml).. Vascular access-and non-vascular access-related hospitalizations were associated with a slightly higher V m and lower V ant ; lower serum albumin concentrations were also associated with higher V m and lower V ant . After adjustment for V ant , graft use was associated with a 5.5% lower V m /V ant , catheter use with a 8.6% higher V m /V ant , vascular access-and non-vascular access-related hospitalizations with a 3.4 and 1.6% higher V m /V ant , respectively, and reductions in serum albumin and weight were respectively associated with increases in V m /V ant of 12.8% per 0.5 mg/L decrease and 2.0% per 5 kg decrease. Table 3 shows the associations of V m and V ant with direct measures of BP and ultrafiltration. After adjustment for V ant , there was no association between V m /V ant and either the predialysis systolic BP (SBP) or diastolic BP (DBP). However, postdialysis SBP and DBP exhibited weak but statistically significant direct correlations with the V m /V ant ratio. There was also a statistically significant direct correlation between change in BP during dialysis and V m /V ant , whether this was expressed as the decline from predialysis SBP to the lowest intradialytic SBP or as the decline from predialysis to postdialysis SBP. The magnitude of the relationship was relatively small, however; e.g., a 10% greater decline from the pre-to postdialysis SBP was associated with a 0.8% lower V m /V ant . Intradialytic hypotension and higher ultrafiltration volume relative to postdialysis body weight were also associated with lower V m /V ant ratios. Figure 1A shows the more pronounced intradialytic SBP decline associated with lower V m /V ant ; Figure 1B shows the relationship relative to the total variation in intradialytic decline in SBP.
Associations among V ant , V m , and V m /V ant and Mortality Table 4 presents the relationship of mortality with the three volume indices. An inverse association was present between V ant and mortality. The relative hazard of a subject with a V ant Ͼ40 L was only 0.3 compared with a patient with V ant Ͻ30 L. For modeled volumes (V m ), the association was reversed, such that a patient with V m Ͼ40 L had a 50% higher mortality hazard compared with a subject with V m Ͻ30 L. After controlling for V ant , the association between V m /V ant and mortality was magnified, showing an approximate threefold increase in risk for subjects in whom the V m /V ant ratio was Ͼ1.1 (110%) compared with those with V m /V ant Ͻ 0.80. Throughout follow-up, 16.6, 34.1, 28.8, 12.8, and 7.8% of V m /V ant measurements were Ͻ0.80, 0.80 to 0.90, 0.90 to 1.00, 1.00 to 1.10, and Ͼ1.10, respectively. A total of 34.3% of subjects had a 4-month mean V m /V ant Ͼ1.10 at least once during follow-up. A further graphical analysis of the joint association of mortality with V ant and V m /V ant is presented in Figure 2 . Higher levels of V m /V ant were associated with marked increases in mortality risk among patients at any given level of V ant .
In contrast to the strong cross-sectional association of V m with V ant , across all follow-up visits, the association of change in 4-month mean V m with contemporaneous change in the 4-month V ant was negligible (Pearson r ϭ 0.07). Hence, we evaluated the association of change in V m with mortality without statistical adjustment for change in V ant . Overall results and results in specific clinical circumstances are presented in Table 5 . In the overall analysis (top panel), mortality was not associated with decreases in V m but was directly associated with increasing V m . The association of increasing V m with mortality was evident regardless of whether the subject's weight was increasing, decreasing, or relatively constant, but was strongest when the subject's weight was increasing. The hazard associated with increasing V m was evident in men and women and was more pronounced in women (interaction P ϭ 0.008). The mortality hazard associated with increasing V m was evident in "smaller" and "larger" patients. Diabetes did 
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Effect of Controlling for V m on Dose-Targeting Bias
The previously reported bias in the relation between achieved eKt/V and mortality (6) was eliminated in the standard dose group and attenuated in the high dose group when the analysis was performed on prescribed eKt/V and adjusted for the running mean modeled volume (V m ) at the time of the preceding prescription change (Figure 3 ).
Sensitivity Analyses
The results shown in Tables 4 and 5 were essentially unchanged after additionally controlling for a more complete set of baseline covariates, including the Karnofsky score, serum albumin, the equilibrated normalized protein catabolic rate, predialysis serum creatinine, predialysis SBP, predialysis DBP, and eight subindices of the ICED (but not the overall ICED itself, to avoid collinearity). Similar results for the association of mortality hazard with V m to those shown in Table 4 and Figure 2 were obtained when the mortality hazard was related to log-transformed V m while controlling for log transformed V ant as a separate covariate.
Discussion
Our results suggest that subjects in the HEMO Study, whether they were assigned to receive the conventional or higher dose of dialysis, were at increased risk of death if they had a high value for modeled urea volume (V m ) or if their value for V m was increasing with time. The association between increasing V m and mortality was magnified after adjusting for patient size (as V ant ) because the relation All HRs are based on time-dependent Cox regressions relating mortality to changes in the 4-month mean V m levels over the preceding 6 months, adjusting for the case mix variables, baseline anthropometric volume, the assigned dose, and flux groups, and the 4-month running mean volume lagged by 6 months. between V m and mortality and V ant and mortality was in opposite directions, as others have reported (19, 20) . The association of mortality with changes in V m was evident across a wide age range, in both genders, in blacks and non-blacks, in subjects with or without diabetes, and across other comorbidities.
To explain the association of V m with mortality, we considered whether increases in V m reflected some technical problem with dialysis delivery that might also be linked to patient risk. An increased in modeled urea volume may not always represent a true increase in total body water, but may be caused by overestimation of the amount of urea removed during dialysis. This can be caused by overestimation of dialysis session length (because of unaccounted-for interruptions) or to overestimation of dialyzer clearance (because of overestimation of blood or dialysate flow rate, dialyzer membrane mass transfer area coefficient [K 0 A]), or time-averaged intradialytic BUN [e.g., because of access recirculation (20) ]. Several scenarios associated with overestimation of dialytic urea removal might conceivably be linked to mortality. For example, subjects with dialysisassociated hypotension resulting in interruptions or reductions in blood flow might have both overestimation of urea removal and a poorer prognosis. We believe that overestimation of urea removal was not the major cause of the observed high values for V m for the following reasons. During each monthly modeled dialysis, clinical symptoms, lowest intradialytic BP, and any interruptions, including those requiring a reduction in blood flow rate, were carefully recorded. We limited our V m mortality analyses to modeled sessions during which treatment interruptions totaled no more than 15 minutes. Higher V m was associated with higher, rather than lower, intradialytic BP, suggesting that hypotension-related interruptions were not the principal cause of increasing V m . For each modeled session, the K 0 A was adjusted for the estimated effects of reprocessing on clearance. Finally, the association between V m and mortality persisted in the conventional dose group, where relatively low blood flow values were used and where there dialysis delivery parameters were not being stressed to deliver the maximum possible dose of dialysis.
The use of intravenous catheters for vascular access has been consistently associated with a lower Kt/V urea relative to fistulas and grafts, because of the inability to deliver higher blood flow rates and possibly because of increased degrees of access recirculation. An increase in V m /V ant was associated with use of a venous catheter and also with use of a fistula versus a graft (perhaps explained by more recirculation at high blood flows in some fistulas). However, the relation of change in V m with mortality was similar in patients using each of the three vascular access types (data not shown) and was also similar during periods with and without vascular access issues (defined as reported access procedures, access-related hospitalizations, or use of an intravenous catheter). Thus, vascular access issues could not adequately explain the association of V m with mortality. Nevertheless, it is possible that some portion of the increases in V m observed were caused by overestimation of urea removal in the kinetic modeling process.
A second hypothesis was that an increased V m is a reflection of fluid overload. We studied the V m -mortality relation under conditions when body weight was increasing, staying more or less constant, or decreasing (Table 5) , and in all three scenarios, increases in V m were associated with mortality. In the situation where both V m and body weight were increasing, the most plausible explanation is that the increase in V m was primarily caused by an increase in extracellular fluid volume. In fact, under these conditions, the relation between increasing V m and mortality risk was the strongest (Table 5 ). In the situation where V m increases but weight is not changed, there are two possible explanations: (1) overestimation of urea removal or (2) patient's "flesh weight" (both muscle and fat) has been lost and has been replaced with fluid. When body weight decreases but V m increases, the increase in fluid more than offsets the loss of flesh weight. In the latter situation, the association between V m and mortality was attenuated, possibly because the V massociated risk was overshadowed by the high mortality risk associated with a falling body weight.
Although not associated with predialysis SBP or DBP per se, higher V m /V ant ratios were associated with higher postdialysis BPs (both systolic and diastolic). Also, higher V m / V ant ratios were associated with smaller falls in SBP during dialysis, whether calculated using the postdialysis SBP or the lowest measured intradialytic BP. These results are consistent with data from Inrig et al. (21, 22) , who found that the highest survival in patients with the greatest intradialytic fall in BP, whereas patients in whom BP did not fall or in whom BP increased, mortality risk was increased. It is tempting to speculate that the increase in V m /V ant and the lower decrement in intradialytic BP in patients in whom V m /V ant was increased were both related to fluid overload. However, our support for this hypothesis must be tempered by the relatively weak strength of the relationships between various BP metrics and V m /V ant .
As shown in Figure 3 , the association between achieved eKt/V and mortality was eliminated in the conventional dose group after adjusting for V m , but only moderately attenuated in the high dose group, which may be more similar to the currently prescribed dialysis dose. Thus, another, as yet unexplored, factor that may further confound the Kt/V-mortality relation may be the numerator of the Kt/V equation; namely, dialysis clearance (K) and session length (t). The relations between changes in K or t and mortality remain a subject for current (23) (24) (25) and future study and analysis.
In summary, we identified a strong and consistent association between modeled urea distribution volume (V m ) and mortality. Based on a series of analyses presented herein, we believe that the association is most likely related to an increase in extracellular water. This interpretation remains speculative, but the association of increased V m with mortality does agree with the relation between bioimpedance-derived evidence of fluid overload and mortality recently published by others (26) .
